{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:53:22Z","timestamp":1787223202327,"version":"build-2736575974"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Multisystem inflammatory syndrome in children (MIS-C) is a postinfectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primarily affecting children. MIS-C shares features with Kawasaki disease (KD) and cytokine storm syndrome (CSS) frequently requiring intensive care support. Although intravenous immunoglobulin (IVIg) and glucocorticoids (GCs) are effective therapeutics for most, refractory MIS-C is treated with various biologic disease-modifying antirheumatic drugs (bDMARDs). Understanding the clinical features, inflammatory cytokines, and genetic associations provides rationale for bDMARD in treating severe MIS-C.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Children with MIS-C have clinical KD features and often present in hypovolemic and cardiogenic shock requiring volume repletion (gastrointestinaI losses) and cardiac pressor support (epinephrine). Investigation of MIS-C serum reveals elevated pro-inflammatory cytokines [interleukin (IL)-1, IL-6, IL-18, interferon gamma (IFN\u03b3), tumor necrosis factor (TNF)], but to a lesser extent than other established CSS. Gene sequencing of MIS-C children identifies heterozygous mutations in CSS associated genes. Treatment of refractory (IVIg and GC) MIS-C with bDMARDs to IL-1, IL-6, and TNF is efficacious for survival as well as resolving cardiac and coronary artery inflammation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>MIS-C is a postinfectious complication of SARS-CoV-2 resembling KD and CSS, both genetically and by pro-inflammatory cytokines. MIS-C that is refractory to IVIg and GC is routinely responsive to bDMARDs targeting IL-1, IL-6, and TNF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000889","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T22:02:42Z","timestamp":1657058562000},"page":"274-279","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children"],"prefix":"10.1097","volume":"34","author":[{"given":"Randy Q.","family":"Cron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"e20200702","DOI":"10.1542\/peds.2020-0702","article-title":"Epidemiology of COVID-19 among children in China","volume":"145","author":"Dong","year":"2020","journal-title":"Pediatrics"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2020.10369","article-title":"Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2","volume":"324","author":"Whittaker","year":"2020","journal-title":"JAMA"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa2021756","article-title":"Multisystem inflammatory syndrome in children in New York state","volume":"383","author":"Dufort","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMoa2021680","article-title":"Multisystem inflammatory syndrome in U.S. children and adolescents","volume":"383","author":"Feldstein","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.15585\/mmwr.mm6940e1","article-title":"Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection \u2013 United Kingdom and United States, March\u2013August 2020","volume":"69","author":"Morris","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-022-01056-8","article-title":"Who would have predicted multisystem inflammatory syndrome in children?","volume":"24","author":"Reiff","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1172\/JCI141113","article-title":"Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12969-021-00508-2","article-title":"Distinguishing active pediatric COVID-19 pneumonia from MIS-C","volume":"19","author":"Reiff","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-020-1054-6","article-title":"Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection","volume":"26","author":"Carter","year":"2020","journal-title":"Nat Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/annrheumdis-2020-217960","article-title":"Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort","volume":"79","author":"Pouletty","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1086\/428291","article-title":"Association between a novel human coronavirus and Kawasaki disease","volume":"191","author":"Esper","year":"2005","journal-title":"J Infect Dis"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/annrheumdis-2020-218110","article-title":"Kawasaki disease or Kawasaki syndrome?","volume":"79","author":"Ravelli","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1172\/JCI140970","article-title":"Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2","volume":"130","author":"Diorio","year":"2020","journal-title":"J Clin Invest"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2102605","article-title":"Multisystem inflammatory syndrome in children \u2013 initial therapy and outcomes","volume":"385","author":"Son","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.41285","article-title":"On the alert for cytokine storm: immunopathology in COVID-19","volume":"72","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41435-020-0098-4","article-title":"The genetics of macrophage activation syndrome","volume":"21","author":"Schulert","year":"2020","journal-title":"Genes Immun"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41423-019-0277-2","article-title":"NK cell detachment from target cells is regulated by successful cytotoxicity and influences cytokine production","volume":"17","author":"Anft","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.20140964","article-title":"Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time","volume":"212","author":"Jenkins","year":"2015","journal-title":"J Exp Med"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.1501284","article-title":"A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis","volume":"196","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.40438","article-title":"Brief report: Novel UNC13D intronic variant disrupting an NF-kappaB enhancer in a patient with recurrent macrophage activation syndrome and systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2014-11-610816","article-title":"Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion","volume":"125","author":"Spessott","year":"2015","journal-title":"Blood"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3899\/jrheum.121233","article-title":"Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome","volume":"40","author":"Strippoli","year":"2013","journal-title":"J Rheumatol"},{"key":"R26-20250526","first-page":"149","article-title":"A Rare STXBP2 mutation in severe COVID-19 and secondary cytokine storm syndrome","volume":"12","author":"Reiff","year":"2022","journal-title":"Life (Basel)"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MOP.0000000000001061","article-title":"Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children","volume":"33","author":"Schulert","year":"2021","journal-title":"Curr Opin Pediatr"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/infdis\/jiv550","article-title":"Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza","volume":"213","author":"Schulert","year":"2016","journal-title":"J Infect Dis"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"e2214985","DOI":"10.1001\/jamanetworkopen.2022.14985","article-title":"Genetic and clinical characteristics of patients in the middle east with multisystem inflammatory syndrome in children","volume":"5","author":"Abuhammour","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1194.e1","DOI":"10.1016\/j.jaci.2020.07.033","article-title":"Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1","volume":"146","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"732.e1","DOI":"10.1016\/j.jaci.2021.06.024","article-title":"Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)","volume":"148","author":"Chou","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaci.2020.09.016","article-title":"Highways to hell: mechanism based management of cytokine storm syndromes","volume":"146","author":"Canna","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"e28897","DOI":"10.1002\/pbc.28897","article-title":"Effect of COVID-19 on anakinra-induced remission in homozygous STX11 hemophagocytosis lymphohistiocytosis","volume":"68","author":"Vagrecha","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R34-20250526","first-page":"417","article-title":"Hemophagocytic lymphohistiocytosis gene variants in multisystem inflammatory syndrome in children","volume":"11","author":"Vagrecha","year":"2022","journal-title":"Biology (Basel)"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood-2017-11-814244","article-title":"Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis","volume":"132","author":"Chinn","year":"2018","journal-title":"Blood"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40272-019-00367-1","article-title":"Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management","volume":"22","author":"Henderson","year":"2020","journal-title":"Paediatr Drugs"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1592.e16","DOI":"10.1016\/j.jaci.2022.02.028","article-title":"Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH)","volume":"149","author":"Kumar","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/art.42062","article-title":"American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3","volume":"74","author":"Henderson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0000000000000609","article-title":"New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases","volume":"27","author":"Norris","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12098-015-1877-1","article-title":"Macrophage activation syndrome","volume":"83","author":"Sen","year":"2016","journal-title":"Indian J Pediatr"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/jpc.15913","article-title":"Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study)","volume":"58","author":"Yilmaz Ciftdogan","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"738850","DOI":"10.3389\/fmed.2021.738850","article-title":"Anti-inflammatory treatment of Kawasaki disease: comparison of current guidelines and perspectives","volume":"8","author":"Buda","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.150108","article-title":"Does viral hemorrhagic fever represent reactive hemophagocytic syndrome?","volume":"42","author":"Cron","year":"2015","journal-title":"J Rheumatol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40272-020-00421-3","article-title":"Anakinra for treatment-resistant kawasaki disease: evidence from a literature review","volume":"22","author":"Ferrara","year":"2020","journal-title":"Paediatr Drugs"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"173.e8","DOI":"10.1016\/j.jpeds.2021.12.035","article-title":"Anakinra treatment in patients with acute Kawasaki disease with coronary artery aneurysms: a phase I\/IIa trial","volume":"243","author":"Yang","year":"2022","journal-title":"J Pediatr"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S2352-4642(21)00270-4","article-title":"Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial","volume":"5","author":"Burns","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00431-021-03935-1","article-title":"SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment","volume":"180","author":"Abdel-Haq","year":"2021","journal-title":"Eur J Pediatr"},{"key":"R52-20250526","first-page":"1","article-title":"Medium-term cardiac outcomes in young people with multisystem inflammatory syndrome: the era of COVID-19","volume":"29","author":"Wong","year":"2022","journal-title":"Pediatr Cardiol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.200334","article-title":"The Rheumatologist's Role in COVID-19","volume":"47","author":"Cron","year":"2020","journal-title":"J Rheumatol"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"e220548","DOI":"10.1001\/jamanetworkopen.2022.0548","article-title":"Mortality rates among hospitalized patients with COVID-19 infection treated with tocilizumab and corticosteroids: a Bayesian reanalysis of a previous meta-analysis","volume":"5","author":"Albuquerque","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"key":"R56-20250526","doi-asserted-by":"crossref","DOI":"10.1177\/08850666221092302","article-title":"Severe multi-inflammatory syndrome in children temporally related to COVID 19-clinical course, laboratory profile and outcomes from a North Indian PICU","author":"Chattopadhyay","year":"2022","journal-title":"J Intensive Care Med"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpeds.2020.06.045","article-title":"Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multiinstitutional study from new York City","volume":"224","author":"Kaushik","year":"2020","journal-title":"J Pediatr"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"982.e14","DOI":"10.1016\/j.cell.2020.09.034","article-title":"Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)","volume":"183","author":"Gruber","year":"2020","journal-title":"Cell"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R62-20250526","first-page":"583","article-title":"Cardiovascular manifestations in multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 according to age","volume":"9","author":"Campanello","year":"2022","journal-title":"Children (Basel)"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3345\/cep.2020.01900","article-title":"Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019","volume":"64","author":"Kwak","year":"2021","journal-title":"Clin Exp Pediatr"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12969-021-00658-3","article-title":"A descriptive study on multisystem inflammatory syndrome in children in a single center in West Michigan","volume":"19","author":"Shabab","year":"2021","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:41Z","timestamp":1748294201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000889","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]}}}